Back to Search
Start Over
The Use of Granulocyte Colony-Stimulating Factor in Clozapine Rechallenge: A Systematic Review
- Source :
- Lally, J, Malik, S, Krivoy, A, Whiskey, E, Taylor, D M, Gaughran, F P, Flanagan, R J, Mijovic, A & Maccabe, J H 2017, ' The Use of Granulocyte Colony-Stimulating Factor in Clozapine Rechallenge : A Systematic Review ', Journal of Clinical Psychopharmacology, vol. 37, no. 5, pp. 600-604 . https://doi.org/10.1097/JCP.0000000000000767
- Publication Year :
- 2017
-
Abstract
- PURPOSE/BACKGROUND: Clozapine is associated with hematological abnormalities, with neutropenia and agranulocytosis of most concern. Granulocyte colony-stimulating factor (G-CSF) has been used to support clozapine rechallenge after neutropenia with the aim of maintaining the neutrophil count. This study aims to explore the practice, use, safety, and efficacy of G-CSF in this context.METHODS/PROCEDURES: We conducted a systematic review to identify all studies investigating or describing G-CSF as a prophylaxis to enable continued clozapine treatment during a rechallenge.FINDINGS/RESULTS: We identified 32 reports of patients who received G-CSF either regularly (n = 23) or as required (n = 9) to support clozapine rechallenge after an episode of neutropenia necessitating discontinuation of clozapine. Seventy-five percent (n = 24) of published cases remained on clozapine with the use of continual prophylactic G-CSF or after single G-CSF administrations (n = 8). Seventy percent (n = 16) of patients in receipt of continual prophylactic G-CSF were successfully maintained on clozapine. However, 1 of the 3 episodes of rechallenge in those with a history of severe agranulocytosis (absolute neutrophil count IMPLICATIONS/CONCLUSIONS: Our findings suggest that G-CSF can sometimes be safely used to support the maintenance of normal neutrophil counts and clozapine use after neutropenia. Publication bias is an important limitation, however. Also, few reports clearly documented the presence or absence of an independent nonclozapine cause of the index neutropenia, which may have increased success rates. Furthermore, adverse events were not systematically recorded. Prospective studies are needed to determine safety because if agranulocytosis occurs on clozapine while supported by G-CSF, there is no obvious alternate rescue therapy to promote granulopoiesis. From the available data, it is not possible to recommend this course of action for someone with a true clozapine agranulocytosis.
- Subjects :
- medicine.medical_specialty
Neutropenia
Context (language use)
G-CSF
treatment-resistant
agranulocytosis
03 medical and health sciences
0302 clinical medicine
Internal medicine
Granulocyte Colony-Stimulating Factor
medicine
neutropenia
Humans
Pharmacology (medical)
Adverse effect
Clozapine
clozapine
granulocyte colony-stimulating factors
business.industry
GM-CSF
Publication bias
medicine.disease
030227 psychiatry
Granulocyte colony-stimulating factor
Discontinuation
schizophrenia
Psychiatry and Mental health
Absolute neutrophil count
business
030217 neurology & neurosurgery
medicine.drug
Antipsychotic Agents
Subjects
Details
- ISSN :
- 1533712X
- Volume :
- 37
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Journal of clinical psychopharmacology
- Accession number :
- edsair.doi.dedup.....a0d2a54a71a325826afface3db2ad7e9
- Full Text :
- https://doi.org/10.1097/JCP.0000000000000767